BTG1失活通过激活BCAR1驱动淋巴瘤发生并促进淋巴瘤播散
本研究探讨BTG1突变在弥漫性大B细胞淋巴瘤(DLBCL)中的功能作用。小鼠实验显示Btg1敲除加速Bcl2过表达驱动的致死性淋巴增殖性疾病发生;BCAR1是BTG1的伙伴蛋白,BTG1缺失或表达患者DLBCL中观察到的BTG1突变后,BCAR1-RAC1通路过度激活,在体外和体内均增强迁移能力,该改变可用SRC抑制剂达沙替尼靶向。
要点
- Btg1敲除加速Bcl2过表达驱动的致死性淋巴增殖性疾病发生。
- BCAR1是BTG1的伙伴蛋白,BTG1缺失或突变导致BCAR1-RAC1通路过度激活。
- BTG1缺失或突变增强体外和体内迁移能力,可用SRC抑制剂达沙替尼靶向。
核心结论
- BTG1失活通过激活BCAR1-RAC1通路驱动淋巴瘤发生并促进淋巴瘤播散,该改变可用SRC抑制剂达沙替尼靶向,为BTG1突变DLBCL提供新的治疗机会。
研究设计与样本
- 本研究为实验性研究,包括Btg1敲除小鼠模型和体外/体内实验,具体样本量原文未报告。
主要发现
- Btg1敲除加速Bcl2过表达驱动的致死性淋巴增殖性疾病发生。
- BCAR1是BTG1的伙伴蛋白。
- BTG1缺失或表达DLBCL患者中观察到的BTG1突变后,BCAR1-RAC1通路过度激活,在体外和体内均增强迁移能力。
临床怎么用
- 原文未据此给出临床推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Understanding the functional role of mutated genes in cancer is required to translate the findings of cancer genomics into therapeutic improvement. BTG1 is recurrently mutated in the MCD/C5 subtype of diffuse large B-cell lymphoma (DLBCL), which is associated with extranodal dissemination. Here, we provide evidence that Btg1 knock out accelerates the development of a lethal lymphoproliferative disease driven by Bcl2 overexpression. Furthermore, we show that the scaffolding protein BCAR1 is a BTG1 partner. Moreover, after BTG1 deletion or expression of BTG1 mutations observed in patients with DLBCL, the overactivation of the BCAR1-RAC1 pathway confers increased migration ability in vitro and in vivo. These modifications are targetable with the SRC inhibitor dasatinib, which opens novel therapeutic opportunities in BTG1 mutated DLBCL.
引用
- Delage L, Lambert M, Bardel É, et al. BTG1 inactivation drives lymphomagenesis and promotes lymphoma dissemination through activation of BCAR1. Blood. 2023. PMID: 36375119. doi:10.1182/blood.2022016943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。